MEET ZYNRELEF®
NOW WITH AN EXPANDED INDICATION
Please see Full Prescribing Information including Boxed Warning
Learn MoreAt Heron, we are unwavering in our commitment to improve the lives of patients. We aim to advance the therapeutic standard of care for patients through a portfolio of best-in-class therapies that bring together our innovative science and technologies with well-known pharmacology to deliver medicines that matter.
At Heron, we understand what is at stake for patients, their caregivers, and families, which is why we are laser-focused on providing solutions that can address unmet medical needs so they can spend more time doing the things that matter with the people who matter.
In the United States each year, 50 million surgeries are performed and the continuing over-reliance on postoperative opioids fuels the crisis by both exposing opioid-naïve patients to narcotics and by leaving hundreds of millions of leftover pills hiding in our community medicine cabinets.1-2
Read MoreOur advanced science, patented technologies, and innovative approach to drug discovery and development have allowed us to create and commercialize a portfolio of products that aim to advance the standard of care for acute care and oncology patients.
CINVANTI® for CINV:
U.S. FDA approved as both a 30-minute intravenous (IV) infusion and a 2-minute IV injection
ZYNRELEF® for Postoperative Pain Management:
HTX-019 for Postoperative Nausea and Vomiting (PONV):
HTX-034 for Postoperative Pain Management
Phase 2 clinical study ongoing for postoperative pain via local application into the surgical site
At Heron, our mission is to improve the lives of patients by developing best-in-class medicines that address unmet medical needs. We are developing novel, patient-focused solutions that apply our innovative science and technologies to already-approved pharmacological agents.
Learn More
June 30 2022
Heron Therapeutics Announces Restructuring and Cost Reduction Plan to Address Market Dynamics and Prepare for Long-Term Sustainability
Read MoreJune 14 2022
Heron Therapeutics Announces Publication Showing ZYNRELEF® as the Foundation of a Perioperative Non-Opioid Multimodal Analgesic Regimen Reduced Severe Pain and Opioid Use in Patients Undergoing Total Knee Arthroplasty
Read MoreMay 26 2022
Heron Therapeutics to Present at the 2022 Jefferies Global Healthcare Conference
Read MoreMay 16 2022
Heron Therapeutics Presents ZYNRELEF® Data at the Society for Obstetric Anesthesia and Perinatology 54th Annual Meeting
Read MoreWe’re looking for people who share our passion and purpose for improving lives of patients.
Learn MoreReceive news and updates on Heron’s latest innovations.